Literature DB >> 22704481

Enzyme replacement therapy improves cardiac features and severity of Fabry disease.

Manish Motwani1, Sanjay Banypersad, Peter Woolfson, Stephen Waldek.   

Abstract

BACKGROUND: Although left ventricular hypertrophy (LVH) in Fabry disease (FD) can improve with enzyme-replacement therapy (ERT), the response is difficult to predict. Furthermore, the response of other cardiac features such as aortic dilatation and ECG changes are poorly understood.
METHODS: A local registry of 66 patients with FD was studied. ECG, echocardiogram and Fabry Outcome Survey-Mainz Severity Score Index (FOS-MSSI) data were compared between baseline and after long-term ERT (median 36 months).
RESULTS: In patients with LVH (n=42), left ventricular mass index (LVMI), maximal wall thickness (MWT), left ventricular end-diastolic diameter (LVEDD) and ejection fraction (EF) were all seen to improve after ERT (LVMI: 135±13 vs. 133±13 g/m(2), MWT: 17±6 vs. 16±5 mm, LVEDD: 55±6 vs. 54±6 mm; EF: 62±5 vs. 64±3%; p<0.05). In the entire patient group, PQ interval and P wave duration significantly increased with ERT (PQ: 131±13 vs. 144±13 ms, P: 76±5 vs. 90±6 ms; p values<0.001); QT(c) interval significantly decreased (418±18 vs. 410±15 ms; p<0.001); and median FOS-MSSI score fell from 16 to 14 (p<0.001). On logistic-regression analysis, none of the recorded baseline features (age, gender, LVMI, MWT, LVEDD, aortic diameter, EF, PQ interval, P wave duration, QRS duration, QT interval, Romhilt-Estes score or FOS-MSSI) predicted improvements in LVH or FOS-MSSI with ERT (p>0.05).
CONCLUSIONS: ERT improved LV morphology and function in patients with LVH - but there was no relationship between age, gender, FOS-MSSI or baseline ECG/TTE features and the response. ERT also normalised long QTc intervals, short PQ intervals and short P waves; and reduced disease burden (FOS-MSSI).
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22704481     DOI: 10.1016/j.ymgme.2012.05.011

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  15 in total

Review 1.  Distribution of late gadolinium enhancement in various types of cardiomyopathies: Significance in differential diagnosis, clinical features and prognosis.

Authors:  Hiroshi Satoh; Makoto Sano; Kenichiro Suwa; Takeji Saitoh; Mamoru Nobuhara; Masao Saotome; Tsuyoshi Urushida; Hideki Katoh; Hideharu Hayashi
Journal:  World J Cardiol       Date:  2014-07-26

Review 2.  Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.

Authors:  Saskia M Rombach; Bouwien E Smid; Gabor E Linthorst; Marcel G W Dijkgraaf; Carla E M Hollak
Journal:  J Inherit Metab Dis       Date:  2014-02-04       Impact factor: 4.982

Review 3.  Restrictive cardiomyopathy in a patient with systemic sclerosis and Fabry disease: a case-based review.

Authors:  Álvaro Arbeláez-Cortés; Diana C Quintero-González; Yesid Cuesta-Astroz; Juan S Villadiego; Herman González-Buriticá; Jorge M Rueda
Journal:  Rheumatol Int       Date:  2019-10-10       Impact factor: 2.631

Review 4.  Disease-targeted sequencing: a cornerstone in the clinic.

Authors:  Heidi L Rehm
Journal:  Nat Rev Genet       Date:  2013-03-12       Impact factor: 53.242

Review 5.  Fabry Disease and the Heart: A Comprehensive Review.

Authors:  Olga Azevedo; Filipa Cordeiro; Miguel Fernandes Gago; Gabriel Miltenberger-Miltenyi; Catarina Ferreira; Nuno Sousa; Damião Cunha
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

6.  Ocular signs correlate well with disease severity and genotype in Fabry disease.

Authors:  Susanne Pitz; Gisela Kalkum; Laila Arash; Nesrin Karabul; Andrea Sodi; Sylvain Larroque; Michael Beck; Andreas Gal
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

7.  Cardiac device implantation in Fabry disease: A retrospective monocentric study.

Authors:  Thomas Sené; Olivier Lidove; Joel Sebbah; Jean-Marc Darondel; Hervé Picard; Laurent Aaron; Olivier Fain; Thierry Zenone; Dominique Joly; Philippe Charron; Jean-Marc Ziza
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

8.  Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study.

Authors:  L J Anderson; K M Wyatt; W Henley; V Nikolaou; S Waldek; D A Hughes; G M Pastores; S Logan
Journal:  J Inherit Metab Dis       Date:  2014-05-15       Impact factor: 4.982

9.  Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A).

Authors:  Hsiang-Yu Lin; Hao-Chuan Liu; Yu-Hsiu Huang; Hsuan-Chieh Liao; Ting-Rong Hsu; Chia-I Shen; Shao-Tzu Li; Cheng-Fang Li; Li-Hong Lee; Pi-Chang Lee; Chun-Kai Huang; Chuan-Chi Chiang; Ching-Yuang Lin; Shuan-Pei Lin; Dau-Ming Niu
Journal:  BMJ Open       Date:  2013-07-16       Impact factor: 2.692

Review 10.  Electrocardiographic Changes and Arrhythmia in Fabry Disease.

Authors:  Mehdi Namdar
Journal:  Front Cardiovasc Med       Date:  2016-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.